Know Cancer

forgot password

Maintenance Alemtuzumab in Refractory Chronic Lymphocytic Leukemia

18 Years
Not Enrolling
Chronic Lymphocytic Leukemia

Thank you

Trial Information

Maintenance Alemtuzumab in Refractory Chronic Lymphocytic Leukemia

This is an open-label, single arm, proof-of-principle study of alemtuzumab maintenance
therapy administered subcutaneously at varying intervals for up to 1 year. Ongoing
prophylactic anti-infectives will be provided. Patients will be assessed for response every
2 months and for quality of life every 3 months while on treatment. Patients achieving a
presumptive complete response will receive no further treatment but will be followed for
response. Non-responding patients, with confirmed progressing disease following a minimum
of 8 doses will be discontinued from treatment and followed for survival. Responding
patients or patients with stable disease will undergo confirmatory assessment 2 months
following their end-of-treatment assessment. If remission has occurred, patients will be
followed off treatment until documented disease progression.

Inclusion Criteria:

- Enrollment in this study is open to patients 18 years of age with confirmed CLL, a
clinical response of stable disease or better to previous treatment, and an Eastern
Cooperative Oncology Group performance status of 0-2

Exclusion Criteria:

- Treatment failure in more than 3 prior regimens

- Active secondary malignancy

- Central nervous system involvement with CLL

- History of significant allergic reaction to antibody therapies that required
discontinuation of the antibody therapy

- History of HIV positivity

- Hepatitis C virus (HCV) positivity based upon core antigen testing

- Active infection, requiring treatment with antibiotic, antiviral, or antifungal

- Pregnancy or lactation

- Other severe, concurrent diseases or mental disorders

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to progression

Outcome Time Frame:

Every 8 weeks

Safety Issue:


Principal Investigator

Kanti R. Rai, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Long Island Jewish Medical Center


United States: Food and Drug Administration

Study ID:




Start Date:

May 2005

Completion Date:

November 2009

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • leukemia
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid



Long Island Jewish Medical CenterNew Hyde Park, New York  11040